Mechanism: Age-dependent epigenetic drift in colonic stem cells drives a SASP, promoting field cancerization and increasing population-level genetic variability. Readout: Readout: DNMT1 inhibition reduces SASP cytokine secretion, decreases tumor incidence, and lowers offspring germline epivariant diversity.
Hypothesis
Age‑dependent epigenetic drift in colonic stem‑cell niches is not random damage but a conserved program that generates field cancerization to increase population‑level genetic variability. This program operates through a senescence‑associated secretory phenotype (SASP) that reshapes the local immune milieu, promoting clonal expansion of epigenetically altered crypts while simultaneously elevating mutagenesis in somatic lineages. The resulting increase in heritable epivariants accelerates adaption, fulfilling an evolvability‑selection role for aging.
Mechanistic Reasoning
- CpG‑shore methylation drift in normal colonic crypts advances with age, creating a bimodal methylation signature that predicts future neoplastic transformation (1).
- Senescent stromal and epithelial cells within these crypts secrete IL‑6, IL‑8, and TGF‑β, establishing a SASP that suppresses cytotoxic T‑cell activity and favors a tolerant microenvironment (7).
- The SASP‑driven immune niche permits clonal expansion of epigenetically altered stem cells, producing the field‑cancerization pattern observed in aged mucosa.
- Concurrently, oxidative stress associated with the SASP elevates somatic point mutations and epimutations in dividing crypt cells, augmenting the genetic diversity shed into the lumen and detectable in fecal microbes.
- This diversity feeds back to the germline via horizontal transfer of extracellular vesicles containing nucleic acids, increasing the variability of offspring genomes and thereby enhancing population evolvability (2, 3).
Testable Predictions
- Prediction 1: Pharmacological inhibition of DNMT1 in aged human colonic organoids will reduce age‑related methylation drift and SASP cytokine secretion without affecting baseline proliferation.
- Prediction 2: Organoids treated with DNMT1 inhibitor will show decreased IL‑6/IL‑8 secretion and reduced ability to promote immune tolerance in co‑cultured autologous T cells.
- Prediction 3: Mice receiving fecal transplants from DNMT1‑inhibited aged donors will exhibit lower fecal epimutation load and reduced tumor incidence in a carcinogen‑induced colitis‑cancer model compared with transplants from untreated aged donors.
- Prediction 4: Offspring of mice transplanted with untreated aged donor microbiota will display higher germline epivariant diversity (measured by whole‑genome bisulfite sequencing of sperm) than offspring receiving microbiota from DNMT1‑inhibited donors.
Falsifiability
If DNMT1 inhibition fails to diminish SASP factor secretion or clonal expansion in aged crypts, or if altering the SASP does not change offspring epigenetic diversity, the hypothesis that programmed epigenetic drift serves as an evolvability mechanism would be refuted. Conversely, confirmation of the predictions would support the view that aging‑linked field cancerization is a selected, adaptive program rather than mere stochastic decay.
Comments
Sign in to comment.